Thank you. Jens and I will start talking about Fostrox, and we can go to the next slide. I just wanted to very briefly go through the scientific rationale for fostrox in HCC. The clinical data we have and what FLEX-HCC will provide are points that Jens has already talked about. So Fostrox, you have already heard this, you can just close your eyes now, but just to level set this so everyone understands what a drug we have. It's an oral prodrug designed for liver cancer. It is activated in the liver, which means that we deliver the active substance, which is troxacitabine, where the tumor is, and keep systemic exposure low. Biopsies from our phase 1b/2 study support this. A study has confirmed this, where the DNA damage is in the tumor tissue, and we could not see any DNA damage in the surrounding healthy liver tissue. And this means that we are sparing the important liver function, allowing it to continue operating effectively. In the phase 1b/2a study, 21 patients with advanced HCC, most of them previously treated with atezolizumab plus bevacizumab. They received fostroxacitabine bralpamide plus lenvatinib as a single-arm treatment, and as a clinician. What I find most convincing is really the consistency of the data we got from this study. The objective response rate was 24%, median time to progression was 10.9 months, and a median overall survival of 13.7 months. And it all pointed in the same direction, consistent with what has been reported. It is consistent with what has been reported in previous second-line studies. The combination was also well tolerated. And only one patient discontinued due to an adverse event. And very important as well is that we did not see an increase in the lenvatinib dose reduction compared to what has been reported with the monotherapy treatment. So what the ongoing FLEX-HCC study will do in this program. First, I would say that the enrollment in FLEX-HCC is according to planned timelines. The plan is to randomize 80 patients with advanced HCC after immunotherapy, and they will receive fostroxacitabine bralpamide plus lenvatinib or lenvatinib. The primary endpoint is response rate. We have already heard that. But the estimated readout is planned during 2027. So next year, what FLEX-HCC will provide is the first randomized data set for fostroxacitabine bralpamide, showing whether the efficacy and safety data points really move in the same direction as we saw in the phase 1B/2A study, and whether the fostroxacitabine bralpamide adds efficacy on top of lenvatinib without adding any toxicity. Those data will really form the basis for a registrational study. And importantly, to understand the treatment algorithm and what the patients have access to, there is still no approved treatment in the second-line, advanced liver cancer setting after immunotherapy. So the need is still very high. You can go to the next slide. So we have talked a bit about FLEX-HCC. But I think it's important to put this study in the context of our development strategy for Fostrox, because it's important to understand what the study is designed to deliver. The phase 1b/2a study gave us a consistent efficacy signal across response rate, time to progression, and overall survival, as I just mentioned, and it was well tolerated. And we also found the recommended phase two dose; FLEX-HCC is the next step. It gives us the first randomized comparison of fostroxacitabine bralpamide plus lenvatinib against lenvatinib alone. It is run by an experienced research consortium in Korea with an estimated readout during 2027. What we are looking for in FLEX-HCC is the direction and the consistency that the response rate, progression-free survival, time to progression, and overall survival all point in the same direction as in the phase 1B/2a, and that Fostrox adds efficacy on top of lenvatinib without adding toxicity. That is the evidence that matters for the next step. So the FLEX-HCC data will really form the basis for a registrational study. And it will also give us advice on the design, the endpoints we should have, the patient population, and the study size. And obviously for our dialogue with regulators, it is very important for discussions with potential partners. So FLEX-HCC is the gateway to partnering and a registrational study, which will take us into pivotal development towards becoming the first approved second-line treatment after immunotherapy.
Next slide.
So last week was a busy week. We attended ESMO in Madrid and, as always, we did not only listen to the scientific presentations, but we also took the opportunity to discuss the new data that was presented with investigators and experts. To better understand what we need to consider in the development of fostroxacitabine bralpamide. These are the key takeaways. The short version is that the second-line opportunity for fostroxacitabine bralpamide plus lenvatinib remains and our strategy is unchanged. The treatment landscape is stable. Immunotherapy combinations remain the first-line standard, and lenvatinib remains the preferred second-line treatment. The LEAP-012 study showed no overall survival benefit when lenvatinib was added to pembrolizumab plus TACE, and that was in intermediate-stage HCC. And this is important to avoid having this systemic treatment already used in the intermediate stage. So we can ensure that this first-line immunotherapy combination remains in the first-line.
The discussed topic at ESMO was GPC3 and the bispecific antibody BGB-B2033 from Biossil. The data are promising, but at the same time, the data are early, with a median follow-up of only 5.5 months, and we did not see any data regarding progression-free survival or overall survival. Naturally, this is due to the very short follow-up. In addition, two important questions remained from the presentation. And that is what is the cutoff that defines GPC3 positivity and what happens to the expression of GPC3 during GPC3-targeted treatment? So there are a couple of questions still remaining. We know that Biossil is starting phase 3 studies across lines of treatment and also across clinical stages. It is a very ambitious program. However, their clear strategic aim is likely to be in first-line, where they want to use the synergy, meaning that the GPC3 expression gets upregulated during anti-PD-1 treatment. They likely want to combine it with their own anti-PD-1, tislelizumab, to get approved in the first-line setting. This is what we strongly believe. So, what does this mean for us? There is still no approved second-line treatment after immunotherapy. And the medical need remains. And with GPC3 bispecific likely moving into first line. Second line after immunotherapy remains open for fostroxacitabine bralpamide plus lenvatinib. Also, with improved first-line treatments, more second-line patients will be eligible for systemic treatment, which means that the Fostrox plus lenvatinib population probably will expand. The experts that we met at ESMO continue to see the strong potential with fostroxacitabine bralpamide in combination with lenvatinib in the second-line setting. So our strategy for fostroxacitabine bralpamide plus lenvatinib is therefore unchanged, and we plan the delivery of the FLEX-HCC study results will be during 2027.
And that will be the basis for the registration study.
Thank you. And we can move to the next slide. So let's move into MIV-711 where we are developing one molecule into two rare bone indications, both without any approved drug treatment today. And preparations for both of these proof-of-concept studies are progressing according to plan. I will start to say a bit about one of them, Osteogenesis Imperfecta. You can go to the next slide. Just as a reminder. Osteogenesis Imperfecta. Or as it is called, brittle bone disease, is a rare genetic disease. It is about 1 in 15,000 births and it is caused by defective or insufficient collagen production. The result is fragile bones that fracture very easily. This results in deformities, short stature, and chronic pain. And there are approximately 500,000 patients globally that are affected by this disease. And no approved disease-modifying treatment is available. The study shown on this slide is our randomized phase 2 proof-of-concept study, where approximately 20 adult patients with OI who have fractured within the previous five years will be enrolled. They will be randomized 1 to 1 to a high or to a low dose of MIV-711 and treated for 12 months. The endpoints are changes in bone biomarkers, which include bone mineral density. We will also look at pharmacokinetics, safety, and number of fractures, and the preparations for this study are progressing according to plan. We have five sites pre-selected and the eligible patients are largely already known to these hospitals, which supports fast enrollment. The preparation of clinical activities is also well underway, and manufacturing of study drug is on schedule, and we continue to see strong commitment from patient organizations. So we can go to the next slide. So looking at MIV-711 as a whole, the work this quarter, as Jens already mentioned, has been focusing on execution. And here, on the manufacturing and the formulation side, the manufacturing of MIV-711 is progressing according to plan. And for Perthes disease, a pediatric oral formulation is a prerequisite for the proof of concept study. And we are following a thorough evaluation. The remaining step is to select the partner before the formulation work begins. The aim is one pediatric formulation that can serve both Perthes disease and Osteogenesis Imperfecta. When we can go into pediatrics there, the foundation of the program is really unchanged: a third-generation, highly selective cathepsin K inhibitor, where we have seen radiographic benefit in around 250 subjects in phase one and two in osteoarthritis. Proof of concept in these specific animal models. Specific animal models. We have Orphan Drug Designation in both indications and Rare Pediatric Disease Designation in Perthes disease. And with that, I hand back to Jens.